A sudy at the Dana-Farber/Brigham found that by five years, 31.8 percent of the men who received hormones had died compared to 19.5 percent of the men who did not receive hormone therapy. In conclusion, researchers say adding hormone therapy to treat prostate cancer may reduce overall survival in men with pre-existing heart conditions. The […]

continue reading from " Adding hormone therapy led to a significant increase in overall mortality. "

Digoxin alters enzymatic pathways for sodium and potassium in heart cells that slows the heart rate while improving pumping action. Recently, a robotic surgery expert who is also a urologic oncologist, said that Digoxin could potentially do the same for prostate cancer.
According to a study by scientists at Johns Hopkins men who used this cardiac drug had a 24 percent […]

continue reading from " Regular Digoxin users had a 24% lower risk of prostate cancer "

Androgen-deprivation therapy (ADT) is a hormone therapy that deprives the patient’s body of androgens, such as testosterone, which have been shown to stimulate the growth of prostate cancer cells
Despite its clinical efficacy in advanced prostate cancer, ADT is associated with an array of adverse side-effects such as insulin resistance and increased risk of cardiovascular disease. […]

continue reading from " Androgen-deprivation therapy is associated with an array of adverse side-effects "

Researchers from VTT Technical Research Centre of Finland and the University of Turku have demonstrated that an antibiotic called “monensin” prevents the growth of prostate cancer cells.
 Researchers found that small amounts of compounds — disulfiram (Antabus), thiram, tricostatin A, and monensin — can prevent the growth of prostate cancer cells without significant effects on the […]

continue reading from " Researchers identified compound that prevents the growth of prostate cancer cells "

Weiyang Liu, an University of Alberta graduate student thonks that the future of cancer treatment is the use of a light-sensitive drug. Liu says the combination of drug treatment and the fibre-optics system could one day replace the long-standing prostate cancer treatments alternatives, chemotherapy or surgery.
The prostate cancer drug is injected into a patient, but only begins […]

continue reading from " Canadian research on light-sensitive drug for prostate cancer "

Jamaican scientist Dr Henry Lowe announced that he had developed a formula that can reduce and eliminate prostate cancer, the number one cause of cancer deaths among males.
Dr. Lowe, executive chairman of Environmental Health Foundation which is based at his Eden Gardens complex in Kingston, explained that the formula will be locally produced, first as […]

continue reading from " Jamaican’s prostate cancer formula for market in three months "

A new report from an independent panel of experts, coordinated by the Institute of Medicine (IOM), has recommended significant changes in the standard daily intake and the upper limits of daily intake of vitamin D.
The precise role of vitamin D in overall management of a variety of aspects of health is still not well established, […]

continue reading from " IOM panel changes recommendations for vitamin D "

A study at the University of Texas Southwestern Medical School suggests that men who use aspirin or other blood thinners after treatment for prostate cancer have a substantially lower risk of dying or seeing the cancer spread to another organ.The new research shows only 4 percent of those taking blood-thinning medications such as aspirin had died […]

continue reading from " Aspirin may reduce prostate cancer deaths "

The results of a study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology in San Diego showed that the use of anticoagulants reduced the risk of dying from the disease from 10 percent to 4 percent at 10 years.  According to study conclusions, taking aspirin in addition to radiation therapy […]

continue reading from " Aspirin cuts the risk of dying in prostate cancer patients "

Queensland University of Technology (QUT) prostate cancer researchers have identified a particular constituent of vitamin E, known as tocotrienol (T3), which can inhibit the growth of prostate tumours.
In trials, ?-T3 completely inhibited tumour formation in more than 70 per cent of the mice implanted with prostate cancer cells and fed the vitamin E constituent in […]

continue reading from " New treatment for prostate cancer: Vitamin E "